Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma.

Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, Mohan S.

Br J Cancer. 2018 Nov 27. doi: 10.1038/s41416-018-0342-0. [Epub ahead of print]

PMID:
30478409
2.

Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma.

Bagley SJ, Schwab RD, Nelson E, Viaene AN, Binder ZA, Lustig RA, O'Rourke DM, Brem S, Desai AS, Nasrallah MP.

J Neurooncol. 2018 Nov 16. doi: 10.1007/s11060-018-03050-6. [Epub ahead of print]

PMID:
30446903
3.

RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Bagley SJ, Hwang WT, Brem S, Linette GP, O'Rourke DM, Desai AS.

J Neurooncol. 2018 Oct 23. doi: 10.1007/s11060-018-03010-0. [Epub ahead of print]

PMID:
30353265
4.

Circulating Glioma Cells Exhibit Stem Cell-like Properties.

Liu T, Xu H, Huang M, Ma W, Saxena D, Lustig RA, Alonso-Basanta M, Zhang Z, O'Rourke DM, Zhang L, Gong Y, Kao GD, Dorsey JF, Fan Y.

Cancer Res. 2018 Dec 1;78(23):6632-6642. doi: 10.1158/0008-5472.CAN-18-0650. Epub 2018 Oct 15.

PMID:
30322863
5.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.

Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD Jr, June CH, Mason NJ, Lin Z, O'Rourke DM, Johnson LA.

Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.

6.

PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma.

Liu T, Ma W, Xu H, Huang M, Zhang D, He Z, Zhang L, Brem S, O'Rourke DM, Gong Y, Mou Y, Zhang Z, Fan Y.

Nat Commun. 2018 Aug 27;9(1):3439. doi: 10.1038/s41467-018-05982-z.

7.

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM.

Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006.

PMID:
29990498
8.

Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.

Chawla S, Wang S, Mohan S, Nasrallah M, Verma G, Brem S, O'Rourke DM, Wolf RL, Poptani H, Nabavizadeh SA.

J Magn Reson Imaging. 2018 Apr 20. doi: 10.1002/jmri.26053. [Epub ahead of print]

PMID:
29676844
9.

In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.

Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O'Rourke DM, Davatzikos C.

Neuro Oncol. 2018 Jul 5;20(8):1068-1079. doi: 10.1093/neuonc/noy033.

PMID:
29617843
10.

Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.

Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O'Rourke DM, Davatzikos C.

Sci Rep. 2018 Mar 23;8(1):5087. doi: 10.1038/s41598-018-22739-2.

11.

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM.

Neuro Oncol. 2018 Oct 9;20(11):1429-1438. doi: 10.1093/neuonc/noy032.

PMID:
29509936
12.

Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α.

Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, Duan H, Ma P, Zhang L, Zamvil SS, Hidalgo J, Zhang Z, O'Rourke DM, Dahmane N, Brem S, Mou Y, Gong Y, Fan Y.

Nat Commun. 2018 Feb 8;9(1):559. doi: 10.1038/s41467-018-03050-0.

13.

Pervasive within-Mitochondrion Single-Nucleotide Variant Heteroplasmy as Revealed by Single-Mitochondrion Sequencing.

Morris J, Na YJ, Zhu H, Lee JH, Giang H, Ulyanova AV, Baltuch GH, Brem S, Chen HI, Kung DK, Lucas TH, O'Rourke DM, Wolf JA, Grady MS, Sul JY, Kim J, Eberwine J.

Cell Rep. 2017 Dec 5;21(10):2706-2713. doi: 10.1016/j.celrep.2017.11.031.

14.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.

Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. No abstract available.

PMID:
29208433
15.

Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma.

Choi BD, O'Rourke DM, Maus MV.

J Target Ther Cancer. 2017 Aug;6(4):22-25.

16.

Pyelonephritis can lead to life-threatening complications.

Keenan DB, O'Rourke DM, Courtney AE.

Practitioner. 2017 Feb;261(1801):17-20.

PMID:
29020720
17.

SHP2 regulates proliferation and tumorigenicity of glioma stem cells.

Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N, O'Rourke DM.

J Neurooncol. 2017 Dec;135(3):487-496. doi: 10.1007/s11060-017-2610-x. Epub 2017 Aug 29.

PMID:
28852935
18.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators.

Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.

19.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

20.

In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The φ-Index.

Bakas S, Akbari H, Pisapia J, Martinez-Lage M, Rozycki M, Rathore S, Dahmane N, O'Rourke DM, Davatzikos C.

Clin Cancer Res. 2017 Aug 15;23(16):4724-4734. doi: 10.1158/1078-0432.CCR-16-1871. Epub 2017 Apr 20.

21.

Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O'Rourke DM, D'Ambrosio A, Bruce JN, Parsa AT.

Clin Cancer Res. 2017 Jul 15;23(14):3575-3584. doi: 10.1158/1078-0432.CCR-16-1369. Epub 2017 Feb 13.

22.

Primary Cell Culture of Live Neurosurgically Resected Aged Adult Human Brain Cells and Single Cell Transcriptomics.

Spaethling JM, Na YJ, Lee J, Ulyanova AV, Baltuch GH, Bell TJ, Brem S, Chen HI, Dueck H, Fisher SA, Garcia MP, Khaladkar M, Kung DK, Lucas TH Jr, O'Rourke DM, Stefanik D, Wang J, Wolf JA, Bartfai T, Grady MS, Sul JY, Kim J, Eberwine JH.

Cell Rep. 2017 Jan 17;18(3):791-803. doi: 10.1016/j.celrep.2016.12.066.

23.

Assignment Confidence in Localization of the Hand Motor Cortex: Comparison of Structural Imaging With Functional MRI.

Sahin N, Mohan S, Maralani PJ, Duddukuri S, O'Rourke DM, Melhem ER, Wolf RL.

AJR Am J Roentgenol. 2016 Dec;207(6):1263-1270. Epub 2016 Sep 13.

PMID:
27622286
24.

Population-based MRI atlases of spatial distribution are specific to patient and tumor characteristics in glioblastoma.

Bilello M, Akbari H, Da X, Pisapia JM, Mohan S, Wolf RL, O'Rourke DM, Martinez-Lage M, Davatzikos C.

Neuroimage Clin. 2016 Mar 12;12:34-40. doi: 10.1016/j.nicl.2016.03.007. eCollection 2016.

25.

Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma.

Doran E, Choy DF, Shikotra A, Butler CA, O'Rourke DM, Johnston JA, Kissenpfennig A, Bradding P, Arron JR, Heaney LG.

Eur Respir J. 2016 Sep;48(3):715-25. doi: 10.1183/13993003.00400-2015. Epub 2016 Jun 23.

26.

c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.

Huang M, Liu T, Ma P, Mitteer RA Jr, Zhang Z, Kim HJ, Yeo E, Zhang D, Cai P, Li C, Zhang L, Zhao B, Roccograndi L, O'Rourke DM, Dahmane N, Gong Y, Koumenis C, Fan Y.

J Clin Invest. 2016 May 2;126(5):1801-14. doi: 10.1172/JCI84876. Epub 2016 Apr 4.

27.

Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma.

Akbari H, Macyszyn L, Da X, Bilello M, Wolf RL, Martinez-Lage M, Biros G, Alonso-Basanta M, OʼRourke DM, Davatzikos C.

Neurosurgery. 2016 Apr;78(4):572-80. doi: 10.1227/NEU.0000000000001202.

28.

Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.

Chowdhury IH, Ojerholm E, McMillan MT, Miller D, Kolker JD, Kurtz G, Dorsey JF, Nagda SN, Geiger GA, Brem S, O'Rourke DM, Zager EL, Gangadhar T, Schuchter L, Lee JY, Alonso-Basanta M.

Radiat Oncol. 2015 Dec 1;10:248. doi: 10.1186/s13014-015-0553-y.

29.

Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases.

Vogel J, Ojerholm E, Hollander A, Briola C, Mooij R, Bieda M, Kolker J, Nagda S, Geiger G, Dorsey J, Lustig R, O'Rourke DM, Brem S, Lee J, Alonso-Basanta M.

Radiat Oncol. 2015 Oct 31;10:221. doi: 10.1186/s13014-015-0523-4.

30.

Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.

Macyszyn L, Akbari H, Pisapia JM, Da X, Attiah M, Pigrish V, Bi Y, Pal S, Davuluri RV, Roccograndi L, Dahmane N, Martinez-Lage M, Biros G, Wolf RL, Bilello M, O'Rourke DM, Davatzikos C.

Neuro Oncol. 2016 Mar;18(3):417-25. doi: 10.1093/neuonc/nov127. Epub 2015 Jul 16.

31.

Factors associated with increased survival after surgical resection of glioblastoma in octogenarians.

Abdullah KG, Ramayya A, Thawani JP, Macyszyn L, Martinez-Lage M, O'Rourke DM, Brem S.

PLoS One. 2015 May 15;10(5):e0127202. doi: 10.1371/journal.pone.0127202. eCollection 2015.

32.

Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.

Walsh AM, Kapoor GS, Buonato JM, Mathew LK, Bi Y, Davuluri RV, Martinez-Lage M, Simon MC, O'Rourke DM, Lazzara MJ.

Mol Cancer Res. 2015 Aug;13(8):1227-37. doi: 10.1158/1541-7786.MCR-14-0183-T. Epub 2015 May 1.

33.

Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas.

Çoban G, Mohan S, Kural F, Wang S, O'Rourke DM, Poptani H.

AJNR Am J Neuroradiol. 2015 Jul;36(7):1247-52. doi: 10.3174/ajnr.A4284. Epub 2015 Apr 2.

34.

Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas.

Jabehdar Maralani P, Melhem ER, Wang S, Herskovits EH, Voluck MR, Kim SJ, Learned KO, O'Rourke DM, Mohan S.

Eur Radiol. 2015 Sep;25(9):2738-44. doi: 10.1007/s00330-015-3640-4. Epub 2015 Feb 14.

PMID:
25680731
35.

Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.

Ojerholm E, Lee JY, Thawani JP, Miller D, O'Rourke DM, Dorsey JF, Geiger GA, Nagda S, Kolker JD, Lustig RA, Alonso-Basanta M.

J Neurosurg. 2014 Dec;121 Suppl:75-83. doi: 10.3171/2014.6.GKS14708.

PMID:
25434940
36.

Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity.

Akbari H, Macyszyn L, Da X, Wolf RL, Bilello M, Verma R, O'Rourke DM, Davatzikos C.

Radiology. 2014 Nov;273(2):502-10. doi: 10.1148/radiol.14132458. Epub 2014 Jun 19.

37.

Postarrest targeted temperature management immediately following craniotomy-a case report.

Delfin G, Leary M, Perman SM, O'Rourke DM, Levine JM, Abella BS.

Ther Hypothermia Temp Manag. 2013 Sep;3(3):143-6. doi: 10.1089/ther.2013.0012. Epub 2013 Jul 11.

PMID:
24834843
38.

Diagnostic utility of diffusion tensor imaging in differentiating glioblastomas from brain metastases.

Wang S, Kim SJ, Poptani H, Woo JH, Mohan S, Jin R, Voluck MR, O'Rourke DM, Wolf RL, Melhem ER, Kim S.

AJNR Am J Neuroradiol. 2014 May;35(5):928-34. doi: 10.3174/ajnr.A3871. Epub 2014 Feb 6.

39.

Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes.

Pal S, Bi Y, Macyszyn L, Showe LC, O'Rourke DM, Davuluri RV.

Nucleic Acids Res. 2014 Apr;42(8):e64. doi: 10.1093/nar/gku121. Epub 2014 Feb 6.

40.

Primary plasmacytoma of the kidney.

Spence RA, Thwaini A, O'Rourke DM.

Case Rep Urol. 2013;2013:239580. doi: 10.1155/2013/239580. Epub 2013 Jul 1.

41.

The complement cascade in kidney disease: from sideline to center stage.

McCaughan JA, O'Rourke DM, Courtney AE.

Am J Kidney Dis. 2013 Sep;62(3):604-14. doi: 10.1053/j.ajkd.2012.12.033. Epub 2013 Mar 13. Review.

PMID:
23489674
42.

Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.

Chawla S, Krejza J, Vossough A, Zhang Y, Kapoor GS, Wang S, O'Rourke DM, Melhem ER, Poptani H.

AJNR Am J Neuroradiol. 2013 Aug;34(8):1542-9. doi: 10.3174/ajnr.A3384. Epub 2013 Jan 31.

43.

Reversion of the ErbB malignant phenotype and the DNA damage response.

Runkle EA, Zhang H, Cai Z, Zhu Z, Karger BL, Wu SL, O'Rourke DM, Zhou Z, Wang Q, Greene MI.

Exp Mol Pathol. 2012 Dec;93(3):324-33. doi: 10.1016/j.yexmp.2012.09.007. Epub 2012 Sep 27. Review.

44.

Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

Tykocinski ES, Grant RA, Kapoor GS, Krejza J, Bohman LE, Gocke TA, Chawla S, Halpern CH, Lopinto J, Melhem ER, O'Rourke DM.

Neuro Oncol. 2012 May;14(5):613-23. doi: 10.1093/neuonc/nos073. Epub 2012 Apr 4.

45.

IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB.

Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.

46.

Survival analysis of patients with high-grade gliomas based on data mining of imaging variables.

Zacharaki EI, Morita N, Bhatt P, O'Rourke DM, Melhem ER, Davatzikos C.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1065-71. doi: 10.3174/ajnr.A2939. Epub 2012 Feb 9.

47.

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.

McCaughan JA, O'Rourke DM, Courtney AE.

Am J Transplant. 2012 Apr;12(4):1046-51. doi: 10.1111/j.1600-6143.2011.03923.x. Epub 2012 Jan 10.

48.

Clinically silent somatotroph adenomas are common.

Wade AN, Baccon J, Grady MS, Judy KD, O'Rourke DM, Snyder PJ.

Eur J Endocrinol. 2011 Jul;165(1):39-44. doi: 10.1530/EJE-11-0216. Epub 2011 Apr 14.

49.

Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging.

Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, O'Rourke DM, Judy KD, Poptani H, Melhem ER.

AJNR Am J Neuroradiol. 2011 Mar;32(3):507-14. doi: 10.3174/ajnr.A2333. Epub 2011 Feb 17.

50.

Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases.

Chawla S, Zhang Y, Wang S, Chaudhary S, Chou C, O'Rourke DM, Vossough A, Melhem ER, Poptani H.

J Comput Assist Tomogr. 2010 Nov-Dec;34(6):836-41. doi: 10.1097/RCT.0b013e3181ec554e.

PMID:
21084897

Supplemental Content

Loading ...
Support Center